EGFR and neoplasm: To that end, we have established a dual-flank tumor xenograft mouse model, carrying human NCI-H358 non-small cell lung cancer (NSCLC) tumors, positive for EGFR and HER2 antigens on one flank, and isogenic NCI-H358 tumors, deficient for HER2 (herein referred to as NCI-H358.HER2.ko) on the opposite flank.